is a partner in the Intellectual Property Practice Group in Sheppard Mullins’ Los Angeles office. Laura focuses on intellectual property litigation with an emphasis on patent law. She is a registered patent attorney, admitted to practice before the U.S. Patent and Trademark Office (USPTO). Laura represents clients in all phases of litigation, including trials, arbitrations and appeals involving intellectual property and technology-related matters. Her clients come from technology areas such as medical devices, chemicals and chemical processes, biotechnology, pharmaceuticals and computers. She is particularly experienced in trial matters, including representing clients in inter partes review and reexamination before the USPTO.
For More information or to contact Laura, please visit her Firm Profile Page.
As COVID-19 continues to rapidly sweep the globe, government agencies at all levels are taking measures to curb the spread of the virus. Private companies have announced plans for and advancements in testing, antivirals and vaccines, leading some members of Congress to raise concerns about whether these medical countermeasures “will be affordable and accessible to the public” in light of companies’ ability to enforce their patent rights and exclude competitors. See Kevin J. Hickey, Cong. Research Serv., LSB10422, COVID-19 Medical Countermeasures: Intellectual Property and Affordability (March 18, 2020). This, in turn, has led to concerns that the government may appropriate private intellectual property rights in order to combat the virus.